Read Article
Related Articles
The lysolipid transporter Mfsd2a regulates lipogenesis in the developing brain
Jia Pei Chan
et al.
PLoS Biology
2018
Blood lysophosphatidylcholine (LPC) levels and characteristic molecular species in neonates: prolonged low blood LPC levels in very low birth weight infants
Akihiro Takatera
et al.
Pediatric Research
2007
Longitudinal Metabolomic Profiling of Amino Acids and Lipids across Healthy Pregnancy
Karen L Lindsay
et al.
PLOS ONE
2015
Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome
Alicia Guemez-Gamboa 1
et al.
Nature Genetics
2015
Quantification of lysophosphatidylcholines and phosphatidylcholines using liquid chromatography-tandem mass spectrometry in neonatal serum
Akihiro Takatera
et al.
Journal of Chromatography B
2006
Insights into major facilitator superfamily domain-contaning protein-2a (Mfsd2a) in physiology and pathophysiology. What do we know so far?
Eser Ocak P
et al.
Journal of Neuroscience Research
2020
Child Head Circumference and Placental MFSD2a Expression Are Associated to the Level of MFSD2a in Maternal Blood During Pregnancy
María Sánchez-Campillo
et al.
Frontiers in Endocrinology
2020
Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism
Justin H Berger
et al.
PLoS ONE
2012
Homozygous mutation in MFSD2A, encoding a lysolipid transporter for docosahexanoic acid, is associated with microcephaly and hypomyelination
Tamar Harel
et al.
Neurogenetics
2018
Maternal lipid levels across pregnancy impact the umbilical cord blood lipidome and infant birth weight
Jennifer L LaBarre
et al.
Scientific Reports
2020
Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease
Richard D Semba
et al.
Advances in Nutrition
2020
Omega-3 PUFA metabolism and brain modifications during aging
Hillary Chappus-McCendie
et al.
Prog Neuropsychopharmacol Biol Psychiatry
2019
Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer's disease
Rhonda P Patrick
et al.
FASEB JOURNAL
2019
Carriers of an apolipoprotein E epsilon 4 allele are more vulnerable to a dietary deficiency in omega-3 fatty acids and cognitive decline
Tanya Gwendolyn Nock
et al.
Biochim Biophys Acta Mol Cell Biol Lipids.
2017
Docosahexaenoic acid prevents cognitive deficits in human apolipoprotein E epsilon 4-targeted replacement mice
Raphaël Chouinard-Watkins
et al.
Neurobiology of Aging
2017
Mechanisms of DHA transport to the brain and potential therapy to neurodegenerative diseases
Amanda Lo Van
et al.
Biochimie
2016
The Cellular and Molecular Landscapes of the Developing Human Central Nervous System
John C Silbereis
et al.
Neuron
2016
A dose response randomised controlled trial of docosahexaenoic acid (DHA) in preterm infants.
C T Collins
et al.
Prostaglandins Leukot Essent Fatty Acids
2015
Pregnancy-induced metabolic phenotype variations in maternal plasma
Hemi Luan
et al.
Journal of Proteome Research
2014
MFSD2a, the Syncytin-2 receptor, is important for trophoblast fusion
C Toufaily
et al.
Placenta
2012
Docosahexaenoic acid (DHA) and the developing central nervous system (CNS) - Implications for dietary recommendations
Philippe Guesnet
et al.
Biochimie
2011
A placenta-specific receptor for the fusogenic, endogenous retrovirus-derived, human syncytin-2
Cécile Esnault
et al.
Proc Natl Acad Sci USA
2008
The aging human orbitofrontal cortex: decreasing polyunsaturated fatty acid composition and associated increases in lipogenic gene expression and stearoyl-CoA desaturase activity
Robert K McNamara
et al.
Prostaglandins Leukot Essent Fatty Acids
2008
The role of essential fatty acids in development
William C Heird
et al.
Annu Rev Nutr
2005
Essential fatty acid transfer and fetal development
S M Innis
et al.
Placenta
2005
Maternal DHA and the development of attention in infancy and toddlerhood
John Colombo
et al.
Child Dev.
2004
Daily Enteral DHA Supplementation Alleviates Deficiency in Premature Infants
Michelle L Baack
et al.
Lipids
2016
Pediatr Res . 2007 Oct;62(4):477-82. doi: 10.1203/PDR.0b013e31814625ca.

Blood lysophosphatidylcholine (LPC) levels and characteristic molecular species in neonates: prolonged low blood LPC levels in very low birth weight infants

October 1, 2007
Akihiro Takatera 1, Atsuko Takeuchi, Kayoko Saiki, Ichiro Morioka, Naoki Yokoyama, Masafumi Matsuo

1Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

Abstract

Lysophosphatidylcholine (LPC) has various stimulatory effects on many types of immune cells. The purpose of our study was to characterize blood LPC levels and to determine the composition of LPC molecular species (LPCs) in the neonatal period. Thirty-six neonates were enrolled in this study and then grouped according to birth-weight as follows: non-very low birth weight (NVLBW); >or=1,500 g (n=17), and very low birth weight (VLBW); <1,500 g (n=19). Sixteen healthy normal adults were used as controls. Levels of total blood LPC and LPCs (16:0-, 18:0-, 18:1-, 18:2-, and 20:4-LPC species) were measured using HPLC coupled with tandem mass spectrometry. Total blood LPC levels at birth in neonates in both groups (NVLBW and VLBW) were significantly lower than those of adult levels. In NVLBW infants, LPC levels reached adult levels at postnatal day 3 compared with VLBW infants, who attained adult levels after postnatal day 57 (around full-term). The composition of the LPCs was different not only between neonates and adults, but between NVLBW and VLBW infants. These findings may be associated with the difference of immunity among adults, NVLBW, and VLBW infants.

Keywords
Early life
Maternal
LPC
Lysolipids
Lysophospholipid
DHA
EPA
RELATED